Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QEQ278 in Advanced Solid Tumors
NCT05462873Phase 1Terminated
- Sponsor
- Novartis
- Start
- Apr 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of QEQ278 in non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), renal cell carcinoma (RCC) and 1 more (2 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 31 months. Started Apr 2023; status: terminated.
02
Drugs
QEQ278
03
Conditions
non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)renal cell carcinoma (RCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05462873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462873.